Posted by Michael Wonder on 19 Sep 2016
Sellas Life Sciences receives FDA fast track designation of galinpepimut-S for the treatment of malignant pleural mesothelioma
19 September 2016 - Follows fast track designation of galinpepimut-S for the treatment of acute myeloid leukaemia.
Sellas Life Sciences today announced that the U.S. FDA has granted fast track designation for galinpepimut-S for the treatment of malignant pleural mesothelioma patients.
The FDA's fast track program is an expedited drug development and review program for new drugs or biologics which show promise in treating serious or life-threatening conditions and address an unmet medical need.
